Literature DB >> 12192621

APOE-epsilon4 and APOE -491A polymorphisms in individuals with subjective memory loss.

S M Laws1, R M Clarnette, K Taddei, G Martins, A Paton, J Hallmayer, O P Almeida, D M Groth, S E Gandy, H Förstl, R N Martins.   

Abstract

The accurate clinical diagnosis of Alzheimer's disease can only be made with a high degree of certainty in specialized centres. The identification of predictive or diagnostic genetic factors may improve accuracy of disease prediction or diagnosis. One major genetic risk factor, the epsilon4 allele of the apolipoprotein E gene, is universally recognised. We have recently shown that the A allele of the apolipoprotein E, -491A/T promoter polymorphism is also an important risk factor for Alzheimer's disease in an Australian population. We designed the present study to investigate the association between apolipoprotein E genotype, -491A/T polymorphism, plasma apoE levels and the subjective experience of memory decline among 98 subjects and 49 age, gender and education-matched normal controls. An increased frequency of the epsilon4 allele of apolipoprotein E was significantly associated with the 'memory complainers' group (OR = 2.35, P = 0.02) as was the A allele of the -491A/T polymorphism (OR = 2, P = 0.02). Among all subjects, only seven individuals were homozygous for both of these alleles, and six of these seven individuals belonged to the 'memory complainers' group. This sub-group also had relatively elevated plasma apolipoprotein E levels (P < 0.01) and tended to score lower on the Mini-Mental State Examination (MMSE) and Cambridge Cognition Test. These data suggest that the epsilon4 allele of apolipoprotein E and the -491A allele are over-represented among individuals who complain of memory difficulties. Follow-up studies should clarify whether these genotypes and phenotypes are useful in the prediction and/or diagnosis of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12192621     DOI: 10.1038/sj.mp.4001083

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  19 in total

1.  The Cognitive Change in Women study (CCW): informant ratings of cognitive change but not self-ratings are associated with neuropsychological performance over 3 years.

Authors:  Rebecca Gavett; Julie E Dunn; Anne Stoddard; Brian Harty; Sandra Weintraub
Journal:  Alzheimer Dis Assoc Disord       Date:  2011 Oct-Dec       Impact factor: 2.703

Review 2.  Candidate mechanisms for chemotherapy-induced cognitive changes.

Authors:  Tim A Ahles; Andrew J Saykin
Journal:  Nat Rev Cancer       Date:  2007-03       Impact factor: 60.716

Review 3.  A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease.

Authors:  Frank Jessen; Rebecca E Amariglio; Martin van Boxtel; Monique Breteler; Mathieu Ceccaldi; Gaël Chételat; Bruno Dubois; Carole Dufouil; Kathryn A Ellis; Wiesje M van der Flier; Lidia Glodzik; Argonde C van Harten; Mony J de Leon; Pauline McHugh; Michelle M Mielke; Jose Luis Molinuevo; Lisa Mosconi; Ricardo S Osorio; Audrey Perrotin; Ronald C Petersen; Laura A Rabin; Lorena Rami; Barry Reisberg; Dorene M Rentz; Perminder S Sachdev; Vincent de la Sayette; Andrew J Saykin; Philip Scheltens; Melanie B Shulman; Melissa J Slavin; Reisa A Sperling; Robert Stewart; Olga Uspenskaya; Bruno Vellas; Pieter Jelle Visser; Michael Wagner
Journal:  Alzheimers Dement       Date:  2014-05-03       Impact factor: 21.566

4.  Subjective cognitive concerns, episodic memory, and the APOE ε4 allele.

Authors:  Cécilia Samieri; Cécile Proust-Lima; Maria M Glymour; Olivia I Okereke; Rebecca E Amariglio; Reisa A Sperling; Dorene M Rentz; Francine Grodstein
Journal:  Alzheimers Dement       Date:  2014-09-23       Impact factor: 21.566

Review 5.  Motoric cognitive risk syndrome: Integration of two early harbingers of dementia in older adults.

Authors:  Richard D Semba; Qu Tian; Michelle C Carlson; Qian-Li Xue; Luigi Ferrucci
Journal:  Ageing Res Rev       Date:  2020-01-26       Impact factor: 10.895

6.  APOE ε4 Genotype and the Risk for Subjective Cognitive Impairment in Elderly Persons.

Authors:  Janina Krell-Roesch; Bryan K Woodruff; Jazmin I Acosta; Dona E Locke; Joseph G Hentz; Cynthia M Stonnington; Gorazd B Stokin; Chelsea Nagle; Bernard F Michel; Nathalie Sambuchi; Richard J Caselli; Yonas E Geda
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2015-03-24       Impact factor: 2.198

Review 7.  Cognitive effects of cytotoxic cancer chemotherapy: predisposing risk factors and potential treatments.

Authors:  Thomas W McAllister; Tim A Ahles; Andrew J Saykin; Robert J Ferguson; Brenna C McDonald; Lionel D Lewis; Laura A Flashman; C Harker Rhodes
Journal:  Curr Psychiatry Rep       Date:  2004-10       Impact factor: 5.285

8.  Functional characterization of three single-nucleotide polymorphisms present in the human APOE promoter sequence: Differential effects in neuronal cells and on DNA-protein interactions.

Authors:  Bryan Maloney; Yuan-Wen Ge; Ronald C Petersen; John Hardy; Jack T Rogers; Jordi Pérez-Tur; Debomoy K Lahiri
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-01-05       Impact factor: 3.568

Review 9.  Cognitive effects of cancer and its treatments at the intersection of aging: what do we know; what do we need to know?

Authors:  Jeanne S Mandelblatt; Arti Hurria; Brenna C McDonald; Andrew J Saykin; Robert A Stern; John W VanMeter; Meghan McGuckin; Tiffani Traina; Neelima Denduluri; Scott Turner; Darlene Howard; Paul B Jacobsen; Tim Ahles
Journal:  Semin Oncol       Date:  2013-12       Impact factor: 4.929

10.  Development of a Human APOE Knock-in Mouse Model for Study of Cognitive Function After Cancer Chemotherapy.

Authors:  Andrew P Speidell; Tamar Demby; Yichien Lee; Olga Rodriguez; Christopher Albanese; Jeanne Mandelblatt; G William Rebeck
Journal:  Neurotox Res       Date:  2018-10-04       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.